35 results about "Calcium influx" patented technology

Cosmetic compositions comprising a metal-complexed peptide fraction of stressed yeast extracts and / or a calcium influx inhibitor are disclosed, as well as methods of using such compositions to impart exfoliating, anti-aging, anti-lipid, anti-inflammatory, and / or lightening benefits to the skin; and / or lightening benefits to the hair. These compositions are believed to have modulatory activity against at least one biochemical pathway implicated in skin aging, inflammation, lipid synthesis, and melanin production.

The present invention pertains to methods to promote outgrowth of, or extension across a substrate of, neuronal cells by inhibiting the interaction between the cytoplasmic tail of the L1-CAM cell surface adhesion molecule and the cytoskeletal protein ankyrin. The invention also pertains to a method to treat diseases characterized by axonal damage such as spinal cord injury, traumatic brain injury, stroke, and neurodegenerative disease by administration of novel peptides that inhibit the binding of the L1-CAM cytoplasmic tail to ankyrin, and to pharmaceutical compositions comprising such peptides. The invention further pertains to a method of blocking calcium flux to protect against neural cell death following stroke or traumatic head injury.

The present invention relates to methods of inhibiting capillary endothelial (CE) cell migration, the formation of CE networks and angiogenesis, and uses thereof for the purpose of treating angiogenesis-related diseases and disorders, particularly when the diseases or disorders are directly related aberrant angiogenesis. Inhibition is achieved by inhibiting TRPV4 activity, such as the levels of TRPV4 expression, calcium influx through TRPV4, and / or the intracellular signaling from TRPV4 via β1 integrin activation.

The invention discloses a CMKLR1 antagonistic polypeptide and derivatives and application thereof, and particularly relates to analogs of the CMKLR1 antagonistic polypeptide shown in sequences SEQ IDNO.1-17 and derivatives thereof. The derivatives of the binding peptide are products obtained after conventional modification of amino terminals or carboxyl terminals on CMKLR1 binding peptide amino acid side chain groups and CMKLR1 antagonistic polypeptide fragments. The binding peptide and the derivatives thereof can be bonded with CMKLR1 in vitro, and by blocking the bond of chemerin and CMKLR1, cAMP concentration increase is promoted, calcium influx caused by chemerin is inhibited and cell chemotaxis caused by chemerin is inhibited. Besides, proliferation of ovarian cancer cells can be inhibited, the cell cycle is blocked, apoptosis of the ovarian cancer cells is promoted, and effective small-molecular treatment drugs are provided for female reproductive diseases such as ovarian cancer.

The invention discloses application of SKF96365 in preparation of a medical composition for treating cerebral angiospasm. According to the invention, a cisterna magna primary blood injection method rat SAH model is adopted to disclose TRPC (Transient Receptor Potential Canonical)1 and TRPC4 expression up-regulation of vascular wall after SAH. The activating level is closely associated with the pathologic change degree of spasm vascular wall in expression time phase, so as to indicate that TRPC1 and TRPC4 participate in occurrence and development of CVS (Cerebral Vascular Spasm). A TRPC channel paralyser SKF96365 is used to prevent and treat cerebral vascular spasm, and the TRPC channel is paralyzed to limit calcium influx of smooth muscle cell, so that the degree of lumen stenosis and lumen thickening can be partially relieved, and a certain treating effect is shown.

The invention provides a preparation method and application of radix astragali saponin. The preparation method of radix astragali saponin comprises the following steps: (1) adding water to radix astragali, extracting by decoction, filtering, and concentrating the filtrate; (2) adding ethanol to precipitate, and standing; (3) recovering the ethanol from the supernatant, diluting with water, injecting into macroporous adsorbent resin columns, and sequentially eluting with water, a 20% (volume / volume) ethanol water solution and a 70% (volume / volume) ethanol water solution; and (4) removing the ethanol in the eluent of the 70% (volume / volume) ethanol water solution, and drying to obtain the radix astragali saponin. The research indicates that the radix astragali saponin can activate the vascular endothelial cell NO-cGMP system, inhibit the calcium influx of vascular smooth muscle cells, and open the K[Ca] and K[ATP] channels, thereby relaxing the smooth muscles, especially vascular smoothmuscles; and therefore, the radix astragali saponin has an obvious function of vasodilatation, and is suitable for preventing and treating cardiovascular diseases, such as lowering the blood pressure, resisting angina pectoris and the like.

A method for treating a mammal comprises administering at least one of a gene, enzyme and pharmaceutical which modulates the concentration of iPLA2β through transcriptional and / or translational regulation or effectively modulate the inhibition of iPLA2β through calmodulin or derivatives thereof.

The present invention discloses a CMKLR1 antagonistic polypeptide and its derivatives and applications, in particular to the sequence SEQ ID No. 1-8 and its derivatives, wherein the derivatives of the polypeptide are CMKLR1 polypeptide amino acid side chain groups, CMKLR1 antagonistic polypeptides The product obtained by conventional modification of the amino-terminus or carboxyl-terminus of the fragment, or the product obtained by linking a tag used for polypeptide or protein detection or purification on the CMKLR1 antagonistic polypeptide; the polypeptide and its derivatives can bind to CMKLR1 in vitro, and through blocking Breaking the combination of chemerin / RvE1 and CMKLR1 changes cAMP concentration, inhibits calcium influx caused by chemerin, and inhibits cell chemotaxis caused by chemerin, providing an effective small molecule drug for the treatment of diseases with high expression of CMKLR1 receptors, which can be used in medicine and biology. widely used in the field of science.